SpringerLink
Log in

CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas

  • T-Cell and Other Lymphoproliferative Malignancies (P Porcu, Section Editor)
  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Evolution of cancer therapeutics has resulted in the development of agents with varying mechanisms of selective target inhibition. One such therapeutic approach is utilizing antibody-drug conjugates (ADCs), the combination of a cytotoxic agent linked with a monoclonal antibody, to achieve localization of the target and internalization of the cytotoxic agent in order to maximize efficacy with fewer toxicities. This review focuses on CD30 as a therapeutic target and the development and clinical activity of the ADC brentuximab vedotin in Hodgkin lymphoma (HL) and other B cell lymphomas.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Agarwal P, Bertozzi CR. Site-specific antibody-drug conjugates: the nexus of bioorthogonal chemistry, protein engineering, and drug development. Bioconjug Chem. 2015;26(2):176–92. doi:10.1021/bc5004982.

    Article  CAS  PubMed  Google Scholar 

  2. Elias DJ, Kline LE, Robbins BA, Johnson Jr HC, Pekny K, Benz M, et al. Monoclonal antibody KS1/4-methotrexate immunoconjugate studies in non-small cell lung carcinoma. Am J Respir Crit Care Med. 1994;150(4):1114–22. doi:10.1164/ajrccm.150.4.7921445.

    Article  CAS  PubMed  Google Scholar 

  3. Arcaini L, Merli M, Passamonti F, Rizzi S, Ferretti V, Rattotti S, et al. Validation of follicular lymphoma international prognostic index 2 (FLIPI2) score in an independent series of follicular lymphoma patients. Br J Haematol. 2010;149(3):455–7. doi:10.1111/j.1365-2141.2009.08065.x.

    Article  PubMed  Google Scholar 

  4. FDA approves Adcetris to treat two types of lymphoma. 2011.

  5. Durkop H, Latza U, Hummel M, Eitelbach F, Seed B, Stein H. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin’s disease. Cell. 1992;68(3):421–7.

    Article  CAS  PubMed  Google Scholar 

  6. Muta H, Podack ER. CD30: from basic research to cancer therapy. Immunol Res. 2013;57(1–3):151–8. doi:10.1007/s12026-013-8464-1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Wahl AF, Klussman K, Thompson JD, Chen JH, Francisco LV, Risdon G, et al. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin’s disease. Cancer Res. 2002;62(13):3736–42.

    CAS  PubMed  Google Scholar 

  8. Borchmann P, Treml JF, Hansen H, Gottstein C, Schnell R, Staak O, et al. The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma. Blood. 2003;102(10):3737–42. doi:10.1182/blood-2003-02-0515.

    Article  CAS  PubMed  Google Scholar 

  9. Schwab U, Stein H, Gerdes J, Lemke H, Kirchner H, Schaadt M, et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin’s disease and a subset of normal lymphoid cells. Nature. 1982;299(5878):65–7.

    Article  CAS  PubMed  Google Scholar 

  10. Gerdes J, Schwarting R, Stein H. High proliferative activity of Reed Sternberg associated antigen Ki-1 positive cells in normal lymphoid tissue. J Clin Pathol. 1986;39(9):993–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Ralfkiaer E, Bosq J, Gatter KC, Schwarting R, Gerdes J, Stein H, et al. Expression of a Hodgkin and Reed-Sternberg cell associated antigen (Ki-1) in cutaneous lymphoid infiltrates. Arch Dermatol Res. 1987;279(5):285–92.

    Article  CAS  PubMed  Google Scholar 

  12. Telford WG, Nam SY, Podack ER, Miller RA. CD30-regulated apoptosis in murine CD8 T cells after cessation of TCR signals. Cell Immunol. 1997;182(2):125–36. doi:10.1006/cimm.1997.1228.

    Article  CAS  PubMed  Google Scholar 

  13. Bowen MA, Lee RK, Miragliotta G, Nam SY, Podack ER. Structure and expression of murine CD30 and its role in cytokine production. J Immunol. 1996;156(2):442–9.

    CAS  PubMed  Google Scholar 

  14. Chiarle R, Podda A, Prolla G, Podack ER, Thorbecke GJ, Inghirami G. CD30 overexpression enhances negative selection in the thymus and mediates programmed cell death via a Bcl-2-sensitive pathway. J Immunol. 1999;163(1):194–205.

    CAS  PubMed  Google Scholar 

  15. DeYoung AL, Duramad O, Winoto A. The TNF receptor family member CD30 is not essential for negative selection. J Immunol. 2000;165(11):6170–3.

    Article  CAS  PubMed  Google Scholar 

  16. Wiley SR, Goodwin RG, Smith CA. Reverse signaling via CD30 ligand. J Immunol. 1996;157(8):3635–9.

    CAS  PubMed  Google Scholar 

  17. Falini B, Pileri S, Pizzolo G, Durkop H, Flenghi L, Stirpe F, et al. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood. 1995;85(1):1–14.

    CAS  PubMed  Google Scholar 

  18. Stein H, Foss HD, Durkop H, Marafioti T, Delsol G, Pulford K, et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000;96(12):3681–95.

    CAS  PubMed  Google Scholar 

  19. Horie R, Watanabe T. CD30: expression and function in health and disease. Semin Immunol. 1998;10(6):457–70. doi:10.1006/smim.1998.0156.

    Article  CAS  PubMed  Google Scholar 

  20. Chiarle R, Podda A, Prolla G, Gong J, Thorbecke GJ, Inghirami G. CD30 in normal and neoplastic cells. Clin Immunol. 1999;90(2):157–64. doi:10.1006/clim.1998.4636.

    Article  CAS  PubMed  Google Scholar 

  21. Gardner LJ, Polski JM, Evans HL, Perkins SL, Dunphy CH. CD30 expression in follicular lymphoma. Arch Pathol Lab Med. 2001;125(8):1036–41. doi:10.1043/0003-9985(2001)125<1036:CEIFL>2.0.CO;2.

    CAS  PubMed  Google Scholar 

  22. Latza U, Foss HD, Durkop H, Eitelbach F, Dieckmann KP, Loy V, et al. CD30 antigen in embryonal carcinoma and embryogenesis and release of the soluble molecule. Am J Pathol. 1995;146(2):463–71.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Ferreiro JA. Ber-H2 expression in testicular germ cell tumors. Hum Pathol. 1994;25(5):522–4.

    Article  CAS  PubMed  Google Scholar 

  24. Hittmair A, Rogatsch H, Hobisch A, Mikuz G, Feichtinger H. CD30 expression in seminoma. Hum Pathol. 1996;27(11):1166–71.

    Article  CAS  PubMed  Google Scholar 

  25. Hu S, Xu-Monette ZY, Balasubramanyam A, Manyam GC, Visco C, Tzankov A, et al. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2013;121(14):2715–24. doi:10.1182/blood-2012-10-461848.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Campuzano-Zuluaga G, Cioffi-Lavina M, Lossos IS, Chapman-Fredricks JR. Frequency and extent of CD30 expression in diffuse large B-cell lymphoma and its relation to clinical and biologic factors: a retrospective study of 167 cases. Leuk Lymphoma. 2013;54(11):2405–11. doi:10.3109/10428194.2013.778407.

    Article  CAS  PubMed  Google Scholar 

  27. Slack GW, Steidl C, Sehn LH, Gascoyne RD. CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia. Br J Haematol. 2014;167(5):608–17. doi:10.1111/bjh.13085.

    Article  CAS  PubMed  Google Scholar 

  28. Wang XJ, Seegmiller AC, Reddy NM, Li S. CD30 expression and its correlation with MYC rearrangement in de novo diffuse large B-cell lymphoma. Eur J Haematol. 2016;97(1):39–47. doi:10.1111/ejh.12680.

    Article  CAS  PubMed  Google Scholar 

  29. Gruss HJ, Pinto A, Gloghini A, Wehnes E, Wright B, Boiani N, et al. CD30 ligand expression in nonmalignant and Hodgkin’s disease-involved lymphoid tissues. Am J Pathol. 1996;149(2):469–81.

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Matsumoto K, Terakawa M, Miura K, Fukuda S, Nakajima T, Saito H. Extremely rapid and intense induction of apoptosis in human eosinophils by anti-CD30 antibody treatment in vitro. J Immunol. 2004;172(4):2186–93.

    Article  CAS  PubMed  Google Scholar 

  31. Hartmann F, Renner C, Jung W, Deisting C, Juwana M, Eichentopf B, et al. Treatment of refractory Hodgkin’s disease with an anti-CD16/CD30 bispecific antibody. Blood. 1997;89(6):2042–7.

    CAS  PubMed  Google Scholar 

  32. Hartmann F, Renner C, Jung W, Pfreundschuh M. Anti-CD16/CD30 bispecific antibodies as possible treatment for refractory Hodgkin’s disease. Leuk Lymphoma. 1998;31(3–4):385–92. doi:10.3109/10428199809059232.

    Article  CAS  PubMed  Google Scholar 

  33. Borchmann P, Schnell R, Fuss I, Manzke O, Davis T, Lewis LD, et al. Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma. Blood. 2002;100(9):3101–7. doi:10.1182/blood-2001-12-0295.

    Article  CAS  PubMed  Google Scholar 

  34. Falini B, Bolognesi A, Flenghi L, Tazzari PL, Broe MK, Stein H, et al. Response of refractory Hodgkin’s disease to monoclonal anti-CD30 immunotoxin. Lancet. 1992;339(8803):1195–6.

    Article  CAS  PubMed  Google Scholar 

  35. Schnell R, Staak O, Borchmann P, Schwartz C, Matthey B, Hansen H, et al. A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin’s and non-Hodgkin’s lymphoma. Clin Cancer Res. 2002;8(6):1779–86.

    CAS  PubMed  Google Scholar 

  36. Schnell R, Borchmann P, Staak JO, Schindler J, Ghetie V, Vitetta ES, et al. Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin’s lymphoma. Ann Oncol. 2003;14(5):729–36.

    Article  CAS  PubMed  Google Scholar 

  37. Schnell R, Dietlein M, Staak JO, Borchmann P, Schomaecker K, Fischer T, et al. Treatment of refractory Hodgkin’s lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody. J Clin Oncol. 2005;23(21):4669–78. doi:10.1200/JCO.2005.09.098.

    Article  CAS  PubMed  Google Scholar 

  38. Ansell SM, Horwitz SM, Engert A, Khan KD, Lin T, Strair R, et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin’s lymphoma and anaplastic large-cell lymphoma. J Clin Oncol. 2007;25(19):2764–9. doi:10.1200/JCO.2006.07.8972.

    Article  CAS  PubMed  Google Scholar 

  39. Bartlett N, Younes A. M C. Phase I study of SGN-30, a chimeric monoclonal antibody (mAb), in patients with refractory or recurrent CD30+ hematologic malignancies. Blood. 2002;100:362a–3a.

    Google Scholar 

  40. Bartlett NL, Younes A, Carabasi MH, Forero A, Rosenblatt JD, Leonard JP, et al. A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood. 2008;111(4):1848–54. doi:10.1182/blood-2007-07-099317.

    Article  CAS  PubMed  Google Scholar 

  41. Forero-Torres A, Leonard JP, Younes A, Rosenblatt JD, Brice P, Bartlett NL, et al. A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol. 2009;146(2):171–9. doi:10.1111/j.1365-2141.2009.07740.x.

    Article  CAS  PubMed  Google Scholar 

  42. Cerveny CG, Law CL, McCormick RS, Lenox JS, Hamblett KJ, Westendorf LE, et al. Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin’s disease cells to conventional chemotherapeutics. Leukemia. 2005;19(9):1648–55. doi:10.1038/sj.leu.2403884.

    Article  CAS  PubMed  Google Scholar 

  43. Heuck F, Ellermann J, Borchmann P, Rothe A, Hansen H, Engert A, et al. Combination of the human anti-CD30 antibody 5F11 with cytostatic drugs enhances its antitumor activity against Hodgkin and anaplastic large cell lymphoma cell lines. J Immunother. 2004;27(5):347–53.

    Article  CAS  PubMed  Google Scholar 

  44. Blum KA, Jung SH, Johnson JL, Lin TS, Hsi ED, Lucas DM, et al. Serious pulmonary toxicity in patients with Hodgkin’s lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcgammaRIIIa-158 V/F polymorphism. Ann Oncol. 2010;21(11):2246–54. doi:10.1093/annonc/mdq211.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Sutherland MS, Sanderson RJ, Gordon KA, Andreyka J, Cerveny CG, Yu C, et al. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J Biol Chem. 2006;281(15):10540–7. doi:10.1074/jbc.M510026200.

    Article  CAS  PubMed  Google Scholar 

  46. Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity [Abstract]. Blood. 2003;102(4):1458–65. doi:10.1182/blood-2003-01-0039.

    Article  CAS  PubMed  Google Scholar 

  47. Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, Cerveny CG, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res. 2004;10(20):7063–70. doi:10.1158/1078-0432.CCR-04-0789.

    Article  CAS  PubMed  Google Scholar 

  48. Okeley NM, Miyamoto JB, Zhang X, Sanderson RJ, Benjamin DR, Sievers EL, et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res. 2010;16(3):888–97. doi:10.1158/1078-0432.CCR-09-2069.

    Article  CAS  PubMed  Google Scholar 

  49. Oflazoglu E, Kissler KM, Sievers EL, Grewal IS, Gerber HP. Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma. Br J Haematol. 2008;142(1):69–73. doi:10.1111/j.1365-2141.2008.07146.x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19):1812–21. doi:10.1056/NEJMoa1002965.

    Article  CAS  PubMed  Google Scholar 

  51. Fanale MA, Forero-Torres A, Rosenblatt JD, Advani RH, Franklin AR, Kennedy DA, et al. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res. 2012;18(1):248–55. doi:10.1158/1078-0432.CCR-11-1425.

    Article  CAS  PubMed  Google Scholar 

  52. Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol. 2006;24(10):1633–42. doi:10.1200/JCO.2005.04.0543.

    Article  CAS  PubMed  Google Scholar 

  53. Forero-Torres A, Fanale M, Advani R, Bartlett NL, Rosenblatt JD, Kennedy DA, et al. Brentuximab vedotin in transplant-naive patients with relapsed or refractory hodgkin lymphoma: analysis of two phase I studies. Oncologist. 2012;17(8):1073–80. doi:10.1634/theoncologist.2012-0133.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30(18):2183–9. doi:10.1200/JCO.2011.38.0410. This pivotal phase II open-label trial lead to accelerated FDA approval of brentuximab vedotin in relapsed/refractory Hodgkin disease after autologous transplant. Objective responses were noted in 75% with complete remissions in 34% of the patients at a median follow-up of 1.5 years.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Wagner-Johnston ND, Bartlett NL, Cashen A, Berger JR. Progressive multifocal leukoencephalopathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin. Leuk Lymphoma. 2012;53(11):2283–6. doi:10.3109/10428194.2012.676170.

    Article  CAS  PubMed  Google Scholar 

  56. Carson KR, Newsome SD, Kim EJ, Wagner-Johnston ND, von Geldern G, Moskowitz CH, et al. Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project. Cancer. 2014;120(16):2464–71. doi:10.1002/cncr.28712.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. von Geldern G, Pardo CA, Calabresi PA, Newsome SD. PML-IRIS in a patient treated with brentuximab. Neurology. 2012;79(20):2075–7. doi:10.1212/WNL.0b013e3182749f17.

    Article  Google Scholar 

  58. Howlader NNA, Krapcho M, Miller D, Bishop K, Altekruse SF, Kosary CL, et al. SEER Cancer Statistics Review, 1975-2013. Bethesda, MD: National Cancer Institute; 2016.

    Google Scholar 

  59. Kuruvilla JKA, Crump M. How I treat relapsed and refractory Hodgkin lymphoma. Blood. 2011;117(16):4208–17. doi:10.1182/blood-2010-09-288373.

    Article  CAS  PubMed  Google Scholar 

  60. Gopal AK, Chen R, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood. 2015;125(8):1236–43. doi:10.1182/blood-2014-08-595801.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Chen R, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2016. doi:10.1182/blood-2016-02-699850.

    Google Scholar 

  62. Bartlett NL, Chen R, Fanale MA, Brice P, Gopal A, Smith SE, et al. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol. 2014;7:24. doi:10.1186/1756-8722-7-24.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Chen R, Palmer JM, Martin P, Tsai N, Kim Y, Chen BT, et al. Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed/refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2015;21(12):2136–40. doi:10.1016/j.bbmt.2015.07.018.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. LaCasce ABG, Sawas A, Caimi P, Agura E, Matous J, Ansell S, et al. Brentuximab vedotin plus bendamustine: a highly active salvage treatment regimen for patients with relapsed or refractory Hodgkin lymphoma [abstract]. Blood. 2015;126:3982.

    Google Scholar 

  65. Moskowitz AJ, Schoder H, Yahalom J, McCall SJ, Fox SY, Gerecitano J, et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosfamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin’s lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol. 2015;16(3):284–92. doi:10.1016/S1470-2045(15)70013-6. Interim analysis of salvage therapy with brentuximab vedotin showed complete remissions prior to autologous transplants when used in combination with other salvage regimens.

    Article  CAS  PubMed  Google Scholar 

  66. Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385(9980):1853–62. doi:10.1016/S0140-6736(15)60165-9.

    Article  CAS  PubMed  Google Scholar 

  67. Younes A, Connors JM, Park SI, Fanale M, O’Meara MM, Hunder NN, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin’s lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol. 2013;14(13):1348–56. doi:10.1016/S1470-2045(13)70501-1.

    Article  CAS  PubMed  Google Scholar 

  68. Connors JAS, Park S, Fanale MA, Younes A. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed advanced stage Hodgkin lymphoma: long term outcomes [Abstract]. San Francisco: American Society of Hematology; 2014. Long term results of phase I open-label dose escalation study of BV in combination with standard chemotherapy (ABVD) in frontline setting has shown increased pulmonary toxicity in the combination. The study was modified to exclude bleomycin and durable responses have been noted in 96% with 3 year overall survival rate of 100%. Phase III trial (ECHELON-1) comparing efficacy and safety of this combination with standard ABVD is ongoing (clinicaltrials.gov; NCT01712490).

    Google Scholar 

  69. Forero-Torres AHB, Sharman JP, Friedberg JW, Berkowitz MJ, Fintel W, Chen R, et al. Brentuximab vedotin monotherapy and in combination with dacarbazine in frontline treatment of Hodgkin lymphoma in patients aged 60 years and above: interim results of a phase 2 study [Abstract]. Blood. 2014;124:294.

    Google Scholar 

  70. Moskowitz AJ, Hamlin Jr PA, Perales MA, Gerecitano J, Horwitz SM, Matasar MJ, et al. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol. 2013;31(4):456–60. doi:10.1200/JCO.2012.45.3308.

    Article  CAS  PubMed  Google Scholar 

  71. Yasenchak CF-TA, Cline-Burkhardt V, Bordoni R, Patel-Donnelly D, Flynn P, Chen R, et al. Brentuximab vedotin in combination with dacarbazine or bendamustine for frontline treatment of Hodgkin lymphoma in patients aged 60 years and above: interim results of a multi-cohort phase 2 study. Orlando, FL: American Society of Hematology; 2015.

    Google Scholar 

  72. Hill BME, Smith M, Hsi E. CD30 immunohistochemical expression in diffuse large B-cell lymphoma is associated with decreased overall survival and the non-germinal center molecular subtype [Abstract]. Blood. 2013;122:4318.

    Google Scholar 

  73. Jacobsen ED, Sharman JP, Oki Y, Advani RH, Winter JN, Bello CM, et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood. 2015;125(9):1394–402. doi:10.1182/blood-2014-09-598763.

    Article  CAS  PubMed  Google Scholar 

  74. NCCN guidelines In: https://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf.

  75. Bartlett NSM, Advani R, Feldman T, Savage K, Palanca-Wessels M, Siddiqi T. Brentuximab vedotin monotherapy in DLBCL patients with undetectable CD30: preliminary results from a phase 2 study. San Francisco, CA: American Society of Hematology; 2014.

    Google Scholar 

  76. Yasenchak CFC, Budde L, Ansell S, Advani R, Holkova B, Halwani A, et al. Brentuximab vedotin in combination with RCHOP as front-line therapy in patients with DLBCL: interim results from a phase 2 study. Blood. 2014;124:1745.

    Google Scholar 

  77. Yasenchak CHA, Advani R, Ansell S, Budde L, Burke J, Farber C, et al. Brentuximab vedotin with RCHOP as frontline therapy in patients with high-intermediate/high-risk diffuse large B cell lymphoma (DLBCL): results from an ongoing phase 2 study [Abstract]. Orlando: American Society of Hematology; 2015. A Phase II trial of combining BV with R-CHOP as frontline treatment in high and high-intermediate risk DLBCL showed higher CR rates in CD30 positive patients with overall response rates of 97% and CR in 80% in interim analysis.

    Google Scholar 

  78. Ward JTJ, Luo J, Wagner-Johnston N, Cashen A, Fehniger T, Bartlett N. A phase I trial of brentuximab vedotin in combination with lenalidomide in relapsed or refractory diffuse large B-cell lymphoma [Abstract]. Orlando: American Society of Hematology; 2015. A phase I trial of lenalidomide in combination with brentuximab vedotin in relapsed/refractory DLBCL showed overall response rate of 53% with complete remissions noted in 41% in interim analysis.

    Google Scholar 

  79. Zheng W, Medeiros LJ, Young KH, Goswami M, Powers L, Kantarjian HH, et al. CD30 expression in acute lymphoblastic leukemia as assessed by flow cytometry analysis. Leuk Lymphoma. 2014;55(3):624–7. doi:10.3109/10428194.2013.820293.

    Article  CAS  PubMed  Google Scholar 

  80. Fathi AT, Preffer FI, Sadrzadeh H, Ballen KK, Amrein PC, Attar EC, et al. CD30 expression in acute myeloid leukemia is associated with FLT3-internal tandem duplication mutation and leukocytosis. Leuk Lymphoma. 2013;54(4):860–3. doi:10.3109/10428194.2012.728596.

    Article  CAS  PubMed  Google Scholar 

  81. Fathi AT, Chen YB. CD30: a new target for ALL? Leuk Lymphoma. 2014;55(3):478–9. doi:10.3109/10428194.2013.823496.

    Article  PubMed  Google Scholar 

  82. Zheng W, Medeiros LJ, Hu Y, Powers L, Cortes JE, Ravandi-Kashani F, et al. CD30 expression in high-risk acute myeloid leukemia and myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk. 2013;13(3):307–14. doi:10.1016/j.clml.2012.12.006.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Schober T, Framke T, Grosshennig A, Klein C, Kreipe H, Maecker-Kolhoff B. CD30 in pediatric post-transplant lymphoproliferative disease after solid organ transplant: characterization of a new therapeutic target. Leuk Lymphoma. 2015;56(3):832–3. doi:10.3109/10428194.2014.941837.

    Article  PubMed  Google Scholar 

  84. Borate U, Mehta A, Reddy V, Tsai M, Josephson N, Schnadig I. Treatment of CD30-positive systemic mastocytosis with brentuximab vedotin. Leuk Res. 2016;44:25–31. doi:10.1016/j.leukres.2016.02.010.

    Article  CAS  PubMed  Google Scholar 

  85. Gandhi MMS, Smith SM, Nabhan C, Evens AM, Winter JN, Gordon LI, et al. Brentuximab vedotin (BV) plus rituximab (R) as frontline therapy for patients (Pts) with Epstein Barr virus (EBV)+ and/or CD30+ lymphoma: phase I results of an ongoing phase I-II study. San Francisco, CA: American Society of Hematology; 2014.

    Google Scholar 

  86. Svoboda JSL, Nasta S, Landsburg D, Mato A, Pro M, Barta S, et al. Brentuximab vedotin in combination with multi-agent chemotherapy is well tolerated and shows promising activity as frontline treatment for primary mediastinal B-cell lymphoma. Orlando, FL: American Society of Hematology; 2015.

    Google Scholar 

  87. Federico MPE, Merli F, Luminari S, Chauvie S, Pellegrini C, Marcheselli L, et al. A pilot phase II study with brentuximab vedotin followed by ABVD in patients with previously untreated Hodgkin lymphoma: a preliminary report. J Clin Oncol. 2014;32:5s2014. suppl; abstr 8507.

    Google Scholar 

  88. Abramson JAJ, LaCasce A, Redd R, Barnes J, Sokol L, Joyce R, et al. Brentuximab vedotin plus AVD for non-bulky limited stage Hodgkin lymphoma: a phase II trial. J Clin Oncol. 2015;33:8505.

    Google Scholar 

  89. Gopal AK, Bartlett NL, Forero-Torres A, Younes A, Chen R, Friedberg JW, et al. Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy. Leuk Lymphoma. 2014;55(10):2328–34. doi:10.3109/10428194.2013.876496.

    Article  CAS  PubMed  Google Scholar 

  90. Sweetenham JWJ, Nadamanee A, Masszi T, Agura E, Holowiecki J, Abidi M, et al. Updated efficacy and safety data from the AETHERA trial of consolidation with brentuximab vedotin after autologous stem cell transplant (ASCT) in Hodgkin lymphoma patients at high risk of relapse [Abstract]. Biol Blood Marrow Transplant. 2016;22(3):S36–7. doi:10.1016/j.bbmt.2015.11.315.

    Article  Google Scholar 

  91. Viviani S GA, Dalto S, Dodero A, Farina L, Bolis S, Rigacci L, Zallio F, Busca A, Bruno B, Mordini N, Parvis G, Corradini P. Brentuximab vedotin (BV) an effective treatment for transplant ineligible patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL). European Hematology Association; June 12: EHA Learning Center. Jun 12, 2015; 100326; 2015.

Download references

Author information

Authors and Affiliations

  1. The Ohio State University James Comprehensive Cancer Center, 420 West 10th Avenue, A348 Starling Loving Hall, Columbus, OH, 43210, USA

    Geetika Bhatt, Kami Maddocks & Beth Christian

Authors
  1. Geetika Bhatt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kami Maddocks
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Beth Christian
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Beth Christian.

Ethics declarations

Conflict of Interest

Geetika Bhatt declares no potential conflicts of interest. Kami Maddocks and Beth Christian have research support from Seattle Genetics, Celgene, and Bristol-Myers Squibb.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on T-Cell and Other Lymphoproliferative Malignancies

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bhatt, G., Maddocks, K. & Christian, B. CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas. Curr Hematol Malig Rep 11, 480–491 (2016). https://doi.org/10.1007/s11899-016-0345-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-016-0345-y

Keywords

Search

Navigation